Government moves to reduce the cost of PBS medicines 20 March 2025 The Federal Government has today that medicines on the Pharmaceutical Benefits Scheme (PBS) will cost no more than $25 from 1 January 2026. In a pre-election commitment that has been , the maximum cost of a PBS prescription will drop from $31.60 to $25. Group CEO Justine Cain welcomed the announcement saying people taking diabetes medicines listed on the PBS will benefit from this cost of living relief. “A person’s bank balance or postcode should not be a barrier to good health. We must ensure medicines are affordable for people who need them. “Last year undertook a cost of living survey which showed that for 61% of people, the cost of diabetes medicines and technologies was their greatest challenge. “Lowering the cost of PBS medicines will help our community with the considerable strain of living with a chronic condition,” Ms Cain said. Diabetes medicines included in the price change include Metformin, Semaglutide, Empagliflozin, Dapagliflozin, and Empagliflozin with metformin. The Federal Government said the investment will cost $689 million over four years and the changes would come into effect on 1 January 2026 in line with regular indexation.
Blog 1 June 2026 Rebuilding after the fall: Brett Findlay’s story of recovery and resilience Brett Findlay had just started a new job when he learnt he had type 1 diabetes. He figured he could manage diabetes by keeping his blood glucose levels consistently low. Then, one fateful day, he had a severe hypo. In this raw episode of Life on the Level, Brett talks about hypo unawareness, rebuilding after trauma, and the enduring strength of family. Continue Reading
Blog 1 June 2026 Life on the level podcast: returning for season 2 Life on the Level podcast is back with season 2. Hosted by young Aussies Isabella Magee and Sebastian Harris, this season explores what it's really like to live with type 1 diabetes; the challenges, the wins, and all the messy bits in between. Continue Reading
News 27 May 2026 Urgent product correction for MiniMed Android App Medtronic and the Therapeutic Goods Administration have issued an Urgent Product Correction for a MiniMed Mobile App Android software version... Continue Reading